题名 | Potential of PKM2 as a drug target in mouse models with type 1 diabetes mellitus |
作者 | |
通讯作者 | Zhou, Zhiguang; Zheng, Peilin |
发表日期 | 2022-04-01
|
DOI | |
发表期刊 | |
EISSN | 2050-4527
|
卷号 | 10期号:4 |
摘要 | ["Background: This study aimed to determine the effect of PKM2 knockout in STZ induced type 1 diabetes mellitus (T1D) mouse models and to explore the possible mechanism.","Method: PKM2fl/fl C573L/6 mouse was backcrossed with Ins-lcre C57BL/6 mouse to generate beta-cell-specific PKM2 knockout mouse after tamoxifen administration. The expression level of PKM2 in pancreas tissues was detected by quantitative reverse-transcription polymerase chain reaction and western blot analysis. The blood glucose levels in STZ induced T1D mouse models were measured to validate the establishment of T1D models. The pathological changes of T1D mouse were examined by hematoxylin and eosin. The oxidative stress (OS) and inflammatory response in T1D mouse were determined by measuring the expression levels of malondialdehyde, superoxide dismutase, and 8-OHdG in pancreatic tissues and the serum levels of interleukin-6 and tumor necrosis factor-alpha. The ability to catabolize glucose was assessed through intraperitoneal glucose tolerance test and insulin tolerance test.","Results: beta-cell-specific PKM2 knockout was successfully achieved in PKM2fl/flcre+ mouse. T1D mouse with PKM2 knockdown had decreased blood glucose level and suppressed cell apoptosis. PKM2 knockout in T1D mouse attenuated beta cell injury. OS and inflammatory response in T1D mouse with PKM2 knockout were also suppressed compared with T1D mouse without PKM2 knockout.","Conclusion: PKM2 knockout in T1D mouse can attenuate OS and inflammatory response as well as decrease blood glucose level, suggesting the potential of PKM2 as a drug target for T1D treatment."] |
关键词 | |
相关链接 | [来源记录] |
收录类别 | |
语种 | 英语
|
学校署名 | 通讯
|
资助项目 | Natural science Foundation of Guangdong Province[2020A1515010085]
; Shenzhen Municipal Science and Technology Innovation Committee Project[JCYJ20190807150619047]
|
WOS研究方向 | Immunology
|
WOS类目 | Immunology
|
WOS记录号 | WOS:000774047500001
|
出版者 | |
来源库 | Web of Science
|
引用统计 |
被引频次[WOS]:1
|
成果类型 | 期刊论文 |
条目标识符 | http://sustech.caswiz.com/handle/2SGJ60CL/328458 |
专题 | 南方科技大学第一附属医院 |
作者单位 | 1.Cent South Univ, Dept Metab & Endocrinol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China 2.Cent South Univ, Natl Clin Res Ctr Metab Dis, Key Lab Diabet Immunol, Minist Educ, Changsha, Hunan, Peoples R China 3.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp,Southern Univ Sci & Technol, Dept Endocrinol,Affiliated Hosp 1, 1017 North Dongmen Rd, Shenzhen 518020, Guangdong, Peoples R China |
通讯作者单位 | 南方科技大学第一附属医院 |
推荐引用方式 GB/T 7714 |
Liu, Junbin,Li, Zhixia,Huang, Gan,et al. Potential of PKM2 as a drug target in mouse models with type 1 diabetes mellitus[J]. IMMUNITY INFLAMMATION AND DISEASE,2022,10(4).
|
APA |
Liu, Junbin,Li, Zhixia,Huang, Gan,Zhou, Zhiguang,&Zheng, Peilin.(2022).Potential of PKM2 as a drug target in mouse models with type 1 diabetes mellitus.IMMUNITY INFLAMMATION AND DISEASE,10(4).
|
MLA |
Liu, Junbin,et al."Potential of PKM2 as a drug target in mouse models with type 1 diabetes mellitus".IMMUNITY INFLAMMATION AND DISEASE 10.4(2022).
|
条目包含的文件 | 条目无相关文件。 |
|
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论